# An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203

> **NCT02573467** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 211 (actual)

## Conditions studied

- Sporadic Inclusion Body Myositis

## Interventions

- **DRUG:** Bimagrumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02573467
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-02
- **Primary completion:** 2016-08-17
- **Final completion:** 2017-02-13
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2018-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02573467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02573467, "An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02573467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*